Alexi Pharmicia Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 07-07-2024
- Paid Up Capital ₹ 5.00 M
as on 07-07-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.17 Cr
as on 07-07-2024
- Satisfied Charges ₹ 1.25 Cr
as on 07-07-2024
- Revenue 2590.09%
(FY 2023)
- Profit 122.42%
(FY 2023)
- Ebitda 318.16%
(FY 2023)
- Net Worth 124.18%
(FY 2023)
- Total Assets 149.02%
(FY 2023)
About Alexi Pharmicia
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹2.17 Cr. The company has closed loans amounting to ₹1.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
Manju Kumari and Sudhir Suman serve as directors at the Company.
- CIN/LLPIN
U24299HP2020PTC008153
- Company No.
008153
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2020
- Date of AGM
08 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Alexi Pharmicia?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manju Kumari  | Director | 20-Oct-2020 | Current |
| Sudhir Suman | Director | 20-Oct-2020 | Current |
Financial Performance of Alexi Pharmicia.
Alexi Pharmicia Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 2590.09% increase. The company also saw a substantial improvement in profitability, with a 122.42% increase in profit. The company's net worth Soared by an impressive increase of 124.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alexi Pharmicia?
Unlock access to Alexi Pharmicia's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Sep 2023 | ₹9.25 M | Open |
Others Creation Date: 05 Sep 2023 | ₹1.25 Cr | Open |
Others Creation Date: 02 Jun 2021 | ₹1.25 Cr | Satisfied |
How Many Employees Work at Alexi Pharmicia?
Unlock and access historical data on people associated with Alexi Pharmicia, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alexi Pharmicia, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alexi Pharmicia's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.